Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PH-762 |
Synonyms | |
Therapy Description |
PH-762 is a PD-1 (PDCD1) targeting RNAi molecule that reduces PD-1 expression, potentially resulting in an increase in CD8-positive T-cells (Journal for ImmunoTherapy of Cancer 2022;10). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PH-762 | PH762|PH 762 | PH-762 is a PD-1 (PDCD1) targeting RNAi molecule that reduces PD-1 expression, potentially resulting in an increase in CD8-positive T-cells (Journal for ImmunoTherapy of Cancer 2022;10). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06014086 | Phase I | PH-762 | Intratumoral PH-762 for Cutaneous Carcinoma | Recruiting | USA | 0 |